Rapid Micro announces availability of Growth Direct Rapid Sterility application

Rapid Micro Biosystems expects the commercial launch of the Growth Direct Rapid Sterility application by mid-year 2024. Sterility testing is the final quality check for microbial contamination before a pharmaceutical product is released for commercial sale and is typically performed in a facility that manufactures products such as biologics or sterile injectables. The Company has developed a novel, proprietary Rapid Sterility application for use with its Growth Direct system. This innovative solution delivers time to organism detection in as little as 12 hours and final time-to-result in as little as one to three days. This capability represents a significant improvement over widely used traditional test methods, which generally require a 14-day endpoint incubation, and provides compelling differentiation when compared to current rapid sterility products. Commercial launch of the Growth Direct Rapid Sterility application is expected by mid-year 2024.